Table 2.
Univariate Analysis of CMV Infection
| Variable | 1-Year Cumulative Incidence of CMV Infection (SE) | HR (95% CI) | P Value |
|---|---|---|---|
| Recipient Age | .013 | ||
| <60 years | 33 (2.6) | 1 | |
| ≥60 years | 44 (3.9) | 1.45 (1.08–1.96) | |
| Recipient Sex | .988 | ||
| Male | 37 (2.7) | 1.00 (0.73–1.36) | |
| Female | 37 (3.7) | 1 | |
| Donor Age | .428 | ||
| <60 years | 36 (2.3) | 0.81 (0.49–1.34) | |
| ≥60 years | 44 (7.9) | 1 | |
| Time on Dialysis | .188 | ||
| ≤24 months | 39 (2.7) | 1 | |
| >24 months | 32 (3.6) | 0.80 (0.59–1.10) | |
| Cold Ischemia Time | .041 | ||
| ≤18 hours | 32 (3.1) | 1 | |
| >18 hours | 42 (3.1) | 1.36 (1.01–1.83) | |
| Delayed Graft Function | .012 | ||
| Yes | 42 (3.2) | 1.46 (1.08–1.96) | |
| No | 32 (2.9) | 1 | |
| CMV Prophylaxis | .017 | ||
| Yes | 33 (2.9) | 1 | |
| No | 41 (3.4) | 1.38 (1.03–1.86) | |
| CMV Serostatus | .594 | ||
| D+/R− | 42 (5.9) | 1 | |
| R+ | 36 (2.4) | 0.89 (0.60–1.33) | |
| Thymoglobulin Treatment | .007 | ||
| Yes | 31 (3.3) | 0.65 (0.48–0.89) | |
| No | 40 (2.9) | 1 | |
| Immunosuppressive Treatment | .032 | ||
| Tacrolimus | 38 (2.2) | 1 | |
| mTOR inhibitor | 6 (5.4) | 0.116 (0.01–0.82) | |
| HLA Mismatch | .143 | ||
| ≤3 | 16 (1.0) | 1 | |
| >3 | 37 (2.2) | 2.83 (0.70–11.43) | |
| Acute Rejection | <.001 | ||
| Yes | 51 (5.2) | 1.98 (1.42–2.75) | |
| No | 33 (2.4) | 1 | |
| IL-18 -607 A/C Polymorphism | .043 | ||
| CA/CC | 38 (2.5) | 1.68 (1.01–2.77) | |
| AA | 24 (5.1) | 1 | |
| IL-18 -137 C/G Polymorphism | .059 | ||
| CG/GG | 37 (2.4) | 2.36 (0.96–5.75) | |
| CC | 17 (7.0) | 1 | |
| IL-18 Haplotype | .043 | ||
| CG carrier | 38 (2.5) | 1.68 (1.01–2.77) | |
| CG noncarrier | 24 (5.1) | 1 |
Abbreviations: CI, confidence interval; CMV, cytomegalovirus; HLA, human leukocyte antigen; HR, hazards ratio; IL, interleukin; mTOR, mammalian target of rapamycin; SE, standard error.